The EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin and Perjeta – part of the company’s defense against Hercept
NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug that has been turned down twice by NICE for patients in England.
Roche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer from recurring after surgery, at the third attempt.
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.
US intelligence services advised the authors of the BIOSECURE Act that that WuXi AppTec shared confidential data on US customers with the Chinese government, according to